Omnicell Company Profile (NASDAQ:OMCL)

About Omnicell (NASDAQ:OMCL)

Omnicell, Inc. provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence. The Automation and Analytics segment is engaged in the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems and related software. The Medication Adherence segment includes the development, manufacturing and selling of consumable medication blister cards, packaging equipment, medication synchronization platform, and ancillary products and services. Its products are used to manage medication administration outside of the hospital setting and include medication adherence products sold under the brand name MTS, Surgichem, SureMed and the Omnicell brand.

Industry, Sector and Symbol:

Sector: Medical
Industry: Medical Software & Technology Services
Sub-Industry: Health Care Technology
Symbol: NASDAQ:OMCL
CUSIP: 68213N10
Web: www.omnicell.com

Capitalization:

Market Cap: $1.85396 billion
Outstanding Shares: 37,454,000

Average Prices:

50 Day Moving Avg: $50.04
200 Day Moving Avg: $43.64
52 Week Range: $30.35 - $52.70

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: 40.24
P/E Growth: 2.26

Sales & Book Value:

Annual Revenue: $680.15 million
Price / Sales: 2.73
Book Value: $12.00 per share
Price / Book: 4.13

Profitability:

EBIDTA: $42.68 million
Net Margins: -1.14%
Return on Equity: 0.41%
Return on Assets: 0.19%

Debt:

Debt-to-Equity Ratio: 0.41%
Current Ratio: 1.40%
Quick Ratio: 1.01%

Misc:

Average Volume: 240,408 shs.
Beta: 0.67
Short Ratio: 20.31

Frequently Asked Questions for Omnicell (NASDAQ:OMCL)

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) released its quarterly earnings data on Thursday, July, 27th. The company reported $0.02 EPS for the quarter, meeting the consensus estimate of $0.02. The company earned $180.90 million during the quarter, compared to the consensus estimate of $174.08 million. Omnicell had a positive return on equity of 0.41% and a negative net margin of 1.14%. The firm's revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.38 EPS. View Omnicell's Earnings History.

When will Omnicell make its next earnings announcement?

Omnicell is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Omnicell.

What guidance has Omnicell issued on next quarter's earnings?

Omnicell updated its FY17 earnings guidance on Thursday, July, 27th. The company provided EPS guidance of $1.22-$1.34 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.28. The company issued revenue guidance of $720-$740 million, compared to the consensus revenue estimate of $729.63 million.Omnicell also updated its Q3 guidance to $0.38-$0.45 EPS.

Where is Omnicell's stock going? Where will Omnicell's stock price be in 2017?

7 brokerages have issued 12 month target prices for Omnicell's shares. Their predictions range from $40.00 to $67.00. On average, they expect Omnicell's share price to reach $51.57 in the next twelve months. View Analyst Ratings for Omnicell.

What are analysts saying about Omnicell stock?

Here are some recent quotes from research analysts about Omnicell stock:

1. Cantor Fitzgerald analysts commented, "Omnicell announced today that White River Health System in North Central Arkansas selected the company’s automated medication management solutions as well as their pharmacy management software." (7/25/2017)
2. According to Zacks Investment Research, "Over the last one month, Omnicell is trading below the Zacks Categorized Medical Information Systems industry. We are concerned about the company’s increasing cost of production and integration expenses. The company’s last reported first quarter report was also disappointing with year-over-year decline in both earnings and revenues. The escalating costs continue to dent margin performance. Weak hospital spending trends and tough competition also pose threats. Yet, the market is optimistic on the growing significance of medication non-adherence where Omnicell is making substantial expansion. The company is also progressing well with its three-pronged growth strategy. We are particularly looking forward to the launch of the XT Series in the quarter which should boost revenue and profitability down the line." (7/4/2017)

Who are some of Omnicell's key competitors?

Some companies that are related to Omnicell include Cotiviti Holdings (COTV), HealthEquity (HQY), Allscripts Healthcare Solutions (MDRX), Evolent Health (EVH), Emis Group Plc (EMIS), Castlight Health, inc. (CSLT), NantHealth (NH), Tabula Rasa Healthcare (TRHC), Craneware plc (CRW), Simulations Plus (SLP), Fluidigm Corporation (FLDM), Medical Transcription Billing, Corp. (MTBC), Constellation Healthcare Tech (CHT) and Press Ganey Holdings (PGND).

Who are Omnicell's key executives?

Omnicell's management team includes the folowing people:

Randall A. Lipps, Chairman of the Board, President, Chief Executive Officer
Peter J. Kuipers, Chief Financial Officer, Executive Vice President
Daniel S. Johnston, Executive Vice President, Chief Legal and Administrative Officer
J. Christopher Drew, Executive Vice President of Sales and Marketing for North American Automation
Nhat H. Ngo, Executive Vice President - Strategy and Business Development
Robin Gene Seim, Executive Vice President, Global Automation and Medication Adherence
Jorge R. Taborga, Executive Vice President - Engineering and Integration Management Office
James T. Judson, Lead Independent Director
Joanne B. Bauer, Independent Director
Vance B. Moore, Independent Director

Who owns Omnicell stock?

Omnicell's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.32%), Vanguard Group Inc. (5.18%), Conestoga Capital Advisors LLC (4.32%), Dimensional Fund Advisors LP (4.22%), Oak Ridge Investments LLC (4.13%) and Daruma Capital Management LLC (3.61%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, J Christopher Drew, James T Judson, Jorge R Taborga, Nhat H Ngo, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Sara J White. View Institutional Ownership Trends for Omnicell.

Who sold Omnicell stock? Who is selling Omnicell stock?

Omnicell's stock was sold by a variety of institutional investors in the last quarter, including Teachers Advisors LLC, Dimensional Fund Advisors LP, Daruma Capital Management LLC, Wells Fargo & Company MN, Systematic Financial Management LP, UBS Asset Management Americas Inc., King Luther Capital Management Corp and Strs Ohio. Company insiders that have sold Omnicell stock in the last year include Dan S Johnston, Gary S Petersmeyer, J Christopher Drew, James T Judson, Jorge R Taborga, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Sara J White. View Insider Buying and Selling for Omnicell.

Who bought Omnicell stock? Who is buying Omnicell stock?

Omnicell's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Principal Financial Group Inc., First Light Asset Management LLC, Russell Investments Group Ltd., Rice Hall James & Associates LLC, BlackRock Inc., Westwood Holdings Group Inc. and Conestoga Capital Advisors LLC. View Insider Buying and Selling for Omnicell.

How do I buy Omnicell stock?

Shares of Omnicell can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Omnicell's stock price today?

One share of Omnicell stock can currently be purchased for approximately $49.50.

MarketBeat Community Rating for Omnicell (NASDAQ OMCL)

Community Ranking:		3.2 out of 5 ( )
Outperform Votes:		227 (Vote Outperform)
Underperform Votes:		129 (Vote Underperform)
Total Votes:		356

MarketBeat's community ratings are surveys of what our community members think about Omnicell and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Omnicell (NASDAQ:OMCL) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	1 Hold Rating, 6 Buy Ratings
Consensus Rating:	Buy (Score: 2.86)
Consensus Price Target:	$51.57 (4.18% upside)

Analysts' Ratings History for Omnicell (NASDAQ:OMCL)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
9/5/2017	Benchmark Co.	Boost Price Target	Buy -> Buy	$55.00 -> $67.00	Medium
7/30/2017	Piper Jaffray Companies	Reiterated Rating	Hold	$40.00	Medium
7/28/2017	Dougherty & Co	Boost Price Target	Buy	$45.00 -> $49.00	High
7/28/2017	Craig Hallum	Boost Price Target	Buy	$46.00 -> $52.00	High
7/25/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$47.00	Medium
4/26/2017	CIBC	Boost Price Target	Outperform	$43.00 -> $53.00	Low
4/25/2017	Oppenheimer Holdings, Inc.	Reiterated Rating	Outperform	$43.00 -> $53.00	High
9/8/2016	Sidoti	Downgrade	Buy -> Neutral	$43.00	N/A
7/29/2016	FBR & Co	Boost Price Target	Outperform	$40.00 -> $41.00	N/A
3/21/2016	Topeka Capital Markets	Lower Price Target	Buy	$38.00 -> $37.00	N/A
11/1/2015	Cowen and Company	Reiterated Rating	Market Perform	$37.00 -> $29.00	N/A

(Data available from 9/25/2015 forward)

Earnings History for Omnicell (NASDAQ:OMCL)

Earnings by Quarter for Omnicell (NASDAQ:OMCL)

Earnings History by Quarter for Omnicell (NASDAQ OMCL)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
10/25/2017		$0.42					N/A
7/27/2017	Q2 2017	$0.02	$0.02	$174.08 million	$180.90 million	View	N/A
5/4/2017	Q1 2017	($0.30)	$0.06	$152.63 million	$150.90 million	View	Listen
2/15/2017	Q4 2016	$0.41	$0.37	$179.28 million	$171.97 million	View	Listen
10/27/2016	Q316	$0.41	$0.40	$179.75 million	$179.40 million	View	Listen
7/28/2016	Q216	$0.32	$0.38	$170.89 million	$175.60 million	View	Listen
4/28/2016	Q116	$0.26	$0.35	$167.18 million	$171.00 million	View	Listen
2/4/2016	Q415	$0.39	$0.40	$126.89 million	$130.30 million	View	Listen
10/29/2015	Q315	$0.36	$0.36	$128.50 million	$125.20 million	View	Listen
7/30/2015	Q215	$0.32	$0.28	$121.35 million	$112.80 million	View	Listen
4/30/2015	Q115	$0.23	$0.29	$112.00 million	$16.20 million	View	N/A
2/3/2015	Q414	$0.33	$0.39	$114.65 million	$121.50 million	View	Listen
10/30/2014	Q314	$0.31	$0.30	$106.10 million	$112.50 million	View	Listen
7/31/2014	Q214	$0.29	$0.30	$103.23 million	$105.10 million	View	Listen
5/1/2014	Q114	$0.24	$0.26	$97.49 million	$101.80 million	View	Listen
2/4/2014	Q413	$0.28	$0.29	$101.13 million	$105.80 million	View	Listen
10/31/2013	Q313	$0.28	$0.31	$94.96 million	$94.03 million	View	N/A
8/1/2013	Q2 2013	$0.25	$0.27	$92.42 million	$93.70 million	View	N/A
5/2/2013	Q1 2013	$0.19	$0.21	$87.20 million	$87.11 million	View	N/A
1/31/2013	Q4 2012	$0.25	$0.25	$87.31 million	$90.16 million	View	N/A
10/25/2012		$0.22	$0.29			View	N/A
8/1/2012		$0.18	$0.20			View	N/A
5/2/2012		$0.13	$0.13			View	N/A
1/26/2012		$0.16	$0.19			View	N/A
10/27/2011		$0.16	$0.16			View	N/A
7/28/2011		$0.13	$0.15			View	N/A
5/2/2011		$0.10	$0.11			View	N/A
1/27/2011		$0.12	$0.11			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Omnicell (NASDAQ:OMCL)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q2 2017	1	$0.12	$0.12	$0.12
Q4 2017	1	$0.32	$0.32	$0.32

(Data provided by Zacks Investment Research)

Dividend History for Omnicell (NASDAQ:OMCL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Omnicell (NASDAQ:OMCL)

Insider Ownership Percentage: 3.77%
Institutional Ownership Percentage: 96.35%

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Insider Trades by Quarter for Omnicell (NASDAQ:OMCL)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/15/2017	Robin Gene Seim	EVP	Sell	9,780	$48.97	$478,926.60
9/5/2017	Gary S. Petersmeyer	Director	Sell	1,000	$51.73	$51,730.00
9/1/2017	Randall A. Lipps	Chairman	Sell	10,625	$52.00	$552,500.00
8/18/2017	Dan S Johnston	EVP	Sell	16,400	$48.86	$801,304.00
8/15/2017	Robin Gene Seim	EVP	Sell	15,109	$50.86	$768,443.74
8/9/2017	Peter J Kuipers	VP	Sell	18,054	$50.31	$908,296.74
8/8/2017	J Christopher Drew	VP	Sell	11,375	$51.16	$581,945.00
8/7/2017	Jorge R Taborga	VP	Sell	20,719	$50.98	$1,056,254.62
8/1/2017	Randall A Lipps	Chairman	Sell	40,000	$49.76	$1,990,400.00
7/28/2017	Randall A Lipps	Chairman	Sell	37,500	$46.00	$1,725,000.00
6/19/2017	Randall A Lipps	Chairman	Sell	31,527	$42.87	$1,351,562.49
6/5/2017	Randall A Lipps	Chairman	Sell	9,900	$43.00	$425,700.00
5/26/2017	James T Judson	Director	Sell	12,148	$41.50	$504,142.00
5/25/2017	Gary S Petersmeyer	Director	Sell	2,200	$41.41	$91,102.00
5/19/2017	Dan S Johnston	EVP	Sell	16,400	$40.67	$666,988.00
5/9/2017	J Christopher Drew	VP	Sell	10,625	$40.97	$435,306.25
4/25/2017	Randall A Lipps	Chairman	Sell	18,200	$41.00	$746,200.00
3/10/2017	Gary S Petersmeyer	Director	Sell	2,658	$37.45	$99,542.10
2/21/2017	Sara J White	Director	Sell	3,443	$38.06	$131,040.58
11/18/2016	Dan S Johnston	EVP	Sell	8,850	$33.65	$297,802.50
11/18/2016	Jorge R Taborga	VP	Sell	2,068	$33.66	$69,608.88
11/8/2016	J Christopher Drew	VP	Sell	20,000	$31.95	$639,000.00
9/12/2016	Gary S Petersmeyer	Director	Sell	2,000	$37.98	$75,960.00
9/8/2016	Gary S Petersmeyer	Director	Sell	2,400	$39.39	$94,536.00
9/6/2016	Gary S Petersmeyer	Director	Sell	2,000	$39.02	$78,040.00
9/2/2016	Gary S Petersmeyer	Director	Sell	3,000	$38.52	$115,560.00
8/19/2016	Dan S Johnston	EVP	Sell	8,850	$36.93	$326,830.50
8/19/2016	Jorge R Taborga	VP	Sell	1,778	$36.92	$65,643.76
8/11/2016	Randall A Lipps	Chairman	Sell	37,425	$37.37	$1,398,572.25
8/9/2016	J Christopher Drew	VP	Sell	15,000	$37.89	$568,350.00
8/9/2016	James T Judson	Director	Sell	6,250	$37.98	$237,375.00
8/4/2016	Gary S Petersmeyer	Director	Sell	8,750	$37.84	$331,100.00
7/29/2016	Jorge R Taborga	VP	Sell	10,023	$40.00	$400,920.00
7/6/2016	Robin Gene Seim	EVP	Sell	5,302	$34.75	$184,244.50
7/1/2016	Robin Gene Seim	EVP	Sell	3,645	$35.00	$127,575.00
6/6/2016	Jorge R Taborga	VP	Sell	25,979	$33.00	$857,307.00
5/24/2016	Gary S Petersmeyer	Director	Sell	6,250	$31.22	$195,125.00
5/20/2016	Dan S Johnston	EVP	Sell	8,850	$30.73	$271,960.50
5/20/2016	Jorge R Taborga	VP	Sell	1,933	$30.73	$59,401.09
5/10/2016	J Christopher Drew	VP	Sell	15,000	$31.63	$474,450.00
5/5/2016	Sara J White	Director	Sell	2,000	$31.76	$63,520.00
4/29/2016	Robin Gene Seim	EVP	Sell	6,407	$31.00	$198,617.00
4/26/2016	Jorge R Taborga	VP	Sell	23,827	$30.00	$714,810.00
4/26/2016	Robin Gene Seim	EVP	Sell	767	$30.00	$23,010.00
2/19/2016	Dan S Johnston	EVP	Sell	8,850	$27.41	$242,578.50
2/19/2016	Jorge R Taborga	VP	Sell	1,685	$27.42	$46,202.70
2/11/2016	Randall A. Lipps	CEO	Sell	40,000	$27.81	$1,112,400.00
2/9/2016	J Christopher Drew	VP	Sell	15,000	$27.57	$413,550.00
12/18/2015	Nhat H. Ngo	VP	Sell	4,069	$28.71	$116,820.99
11/17/2015	Dan S. Johnston	VP	Sell	2,500	$28.00	$70,000.00
11/10/2015	J Christopher Drew	VP	Sell	25,000	$26.79	$669,750.00
11/9/2015	Dan S. Johnston	VP	Sell	2,700	$27.29	$73,683.00
10/13/2015	Gary S. Petersmeyer	Director	Sell	670	$31.66	$21,212.20
8/13/2015	Robin Gene Seim	CFO	Sell	23,946	$35.63	$853,195.98
7/1/2015	Robin Gene Seim	CFO	Sell	19,582	$37.84	$740,982.88
6/17/2015	Nhat H Ngo	VP	Sell	4,067	$38.78	$157,718.26
6/2/2015	James T Judson	Director	Sell	8,032	$36.83	$295,818.56
6/2/2015	Nhat H Ngo	VP	Sell	6,375	$36.80	$234,600.00
5/26/2015	Sara J White	Director	Sell	4,000	$36.25	$145,000.00
5/7/2015	Dan S Johnston	VP	Sell	7,715	$34.25	$264,238.75
2/12/2015	J Christopher Drew	VP	Sell	25,000	$34.62	$865,500.00
2/6/2015	Dan S Johnston	VP	Sell	6,552	$33.29	$218,116.08
2/2/2015	James T Judson	Director	Sell	5,000	$31.61	$158,050.00
1/13/2015	Gary S Petersmeyer	Director	Sell	670	$31.31	$20,977.70
1/2/2015	James T Judson	Director	Sell	5,000	$32.36	$161,800.00
1/2/2015	Robin Gene Seim	CFO	Sell	1,948	$32.36	$63,037.28
12/17/2014	Marga Ortigas-Wedekind	VP	Sell	4,080	$32.20	$131,376.00
12/15/2014	Gary S Petersmeyer	Director	Sell	670	$33.25	$22,277.50
12/8/2014	Nhat H Ngo	VP	Sell	1,754	$32.89	$57,689.06
12/1/2014	James T Judson	Director	Sell	5,000	$31.94	$159,700.00
11/12/2014	Randy D Lindholm	Director	Sell	5,000	$31.72	$158,600.00
11/11/2014	J Christopher Drew	VP	Sell	37,500	$31.86	$1,194,750.00
11/7/2014	Dan S Johnston	VP	Sell	27,625	$31.74	$876,817.50
11/3/2014	James T Judson	Director	Sell	5,000	$32.27	$161,350.00
10/3/2014	Nhat H Ngo	VP	Sell	2,275	$28.00	$63,700.00
10/1/2014	James T Judson	Director	Sell	5,000	$27.02	$135,100.00
9/15/2014	Jorge R Taborga	VP	Sell	944	$26.37	$24,893.28
9/15/2014	Robin Gene Seim	CFO	Sell	9,347	$26.32	$246,013.04
9/2/2014	James T Judson	Director	Sell	5,000	$28.18	$140,900.00
9/2/2014	Robin Gene Seim	CFO	Sell	27,500	$28.19	$775,225.00
8/26/2014	Dan S Johnston	VP	Sell	6,250	$28.00	$175,000.00
8/26/2014	James T Judson	Director	Sell	9,913	$27.91	$276,671.83
7/9/2014	Robin Gene Seim	CFO	Sell	2,442	$28.21	$68,888.82
7/1/2014	James T Judson	Director	Sell	5,000	$29.28	$146,400.00
6/26/2014	Marga Ortigas-Wedekind	VP	Sell	2,961	$28.17	$83,411.37
6/25/2014	Nhat H Ngo	VP	Sell	2,274	$28.00	$63,672.00
6/17/2014	Nhat H Ngo	VP	Sell	1,420	$27.70	$39,334.00
6/10/2014	Nhat H Ngo	VP	Sell	1,964	$26.38	$51,810.32
6/2/2014	Gary S Petersmeyer	Director	Sell	5,000	$26.45	$132,250.00
5/21/2014	Gary Petersmeyer	Director	Sell	2,000	$26.51	$53,020.00
5/13/2014	J Christopher Drew	VP	Sell	37,500	$26.08	$978,000.00
5/7/2014	Dan Johnston	VP	Sell	4,000	$25.25	$101,000.00
5/1/2014	James Judson	Director	Sell	5,000	$26.24	$131,200.00
4/8/2014	Nhat Ngo	VP	Sell	1,002	$27.40	$27,454.80
3/18/2014	Marga Ortigas-Wedekind	VP	Sell	5,880	$30.00	$176,400.00
3/18/2014	Randall Lipps	CEO	Sell	124,910	$29.89	$3,733,559.90
12/18/2013	Nhat Ngo	VP	Sell	1,462	$24.43	$35,716.66
12/18/2013	Randall Lipps	CEO	Sell	64,739	$24.30	$1,573,157.70
12/3/2013	Dan Johnston	VP	Sell	73,419	$23.24	$1,706,257.56
11/11/2013	Randy Lindholm	Director	Sell	3,587	$23.00	$82,501.00
11/7/2013	Dan Johnston	VP	Sell	8,000	$22.99	$183,920.00
10/23/2013	Robin Gene Seim	CFO	Sell	7,664	$24.50	$187,768.00
10/21/2013	Robin Gene Seim	CFO	Sell	9,349	$23.76	$222,132.24
10/1/2013	James T Judson	Director	Sell	5,000	$23.66	$118,300.00
9/24/2013	Randall Lipps	CEO	Sell	68,204	$25.00	$1,705,100.00
9/23/2013	Marga Ortigas-Wedekind	VP	Sell	4,000	$25.00	$100,000.00
9/23/2013	Randall Lipps	CEO	Sell	5,083	$25.00	$127,075.00
9/20/2013	Robin Gene Seim	CFO	Sell	27,500	$24.35	$669,625.00
9/18/2013	Randall Lipps	CEO	Sell	64,453	$23.67	$1,525,602.51
9/4/2013	Nhat H Ngo	VP	Sell	7,362	$24.00	$176,688.00
9/3/2013	James Judson	Director	Sell	5,000	$22.77	$113,850.00
8/20/2013	James Judson	Director	Sell	11,724	$22.74	$266,603.76
8/13/2013	J Christopher Drew	VP	Sell	20,000	$22.83	$456,600.00
8/12/2013	Donald Wegmiller	Director	Sell	34,976	$22.87	$799,901.12
8/7/2013	Dan Johnston	VP	Sell	8,000	$22.92	$183,360.00
8/6/2013	Randall Lipps	CEO	Sell	5,321	$23.00	$122,383.00
8/2/2013	Randall A Lipps	CEO	Sell	25,000	$22.50	$562,500.00
8/1/2013	James Judson	Director	Sell	5,000	$21.00	$105,000.00
7/19/2013	Nhat H Ngo	VP	Sell	41,875	$21.00	$879,375.00
7/19/2013	Randall A Lipps	CEO	Sell	5,080	$21.00	$106,680.00
7/1/2013	James T Judson	Director	Sell	5,000	$20.46	$102,300.00
7/1/2013	Robin Gene Seim	CFO	Sell	13,032	$20.42	$266,113.44
6/28/2013	Marga Ortigas-Wedekind	VP	Sell	4,545	$20.00	$90,900.00
6/28/2013	Randall A Lipps	CEO	Sell	25,000	$20.00	$500,000.00
6/21/2013	Nhat H Ngo	VP	Sell	3,459	$19.01	$65,755.59
6/18/2013	Randall A Lipps	CEO	Sell	66,378	$19.10	$1,267,819.80
6/10/2013	Randy D Lindholm	Director	Sell	23,901	$19.14	$457,465.14
6/4/2013	Robin Gene Seim	CFO	Sell	25,000	$18.72	$468,000.00
5/22/2013	Gary S Petersmeyer	Director	Sell	2,750	$18.10	$49,775.00
5/16/2013	J Christopher Drew	VP	Sell	26,000	$18.69	$485,940.00
5/14/2013	J Christopher Drew	VP	Sell	26,000	$18.45	$479,700.00
5/10/2013	Sara J White	Director	Sell	7,200	$18.50	$133,200.00
5/7/2013	Dan S Johnston	VP	Sell	8,000	$18.44	$147,520.00
12/3/2012	Gary S Petersmeyer	Director	Sell	1,359	$15.17	$20,616.03

(Data available from 1/1/2013 forward)

Headline Trends for Omnicell (NASDAQ:OMCL) Latest Headlines for Omnicell (NASDAQ:OMCL)

Source:

Date	Headline
	Omnicell, Inc. breached its 50 day moving average in a Bearish Manner : OMCL-US : September 20, 2017 finance.yahoo.com - September 22 at 7:20 AM
	Omnicell, Inc. – Value Analysis (NASDAQ:OMCL) : September 21, 2017 finance.yahoo.com - September 22 at 7:20 AM
	$191.88 Million in Sales Expected for Omnicell, Inc. (OMCL) This Quarter www.americanbankingnews.com - September 19 at 12:02 PM
	Omnicell, Inc. (OMCL) EVP Robin Gene Seim Sells 9,780 Shares www.americanbankingnews.com - September 15 at 7:44 PM
	Analyzing Omnicell (OMCL) & Its Rivals www.americanbankingnews.com - September 14 at 10:22 PM
	Omnicell (OMCL) versus Evolent Health (EVH) Critical Contrast www.americanbankingnews.com - September 14 at 12:26 AM
	Contrasting Omnicell (OMCL) and its Rivals www.americanbankingnews.com - September 10 at 6:26 PM
	Omnicell, Inc. (OMCL) Price Target Raised to $67.00 at Benchmark Co. www.americanbankingnews.com - September 6 at 12:52 AM
	Omnicell, Inc. (OMCL) Director Sells $51,730.00 in Stock www.americanbankingnews.com - September 5 at 8:32 PM
	Head-To-Head Review: Omnicell (OMCL) vs. Press Ganey Holdings (PGND) www.americanbankingnews.com - September 2 at 8:28 PM
	Omnicell, Inc. (OMCL) Receives Average Recommendation of "Buy" from Brokerages www.americanbankingnews.com - September 2 at 2:40 PM
	Insider Selling: Omnicell, Inc. (OMCL) Chairman Sells 10,625 Shares of Stock www.americanbankingnews.com - September 1 at 7:42 PM
	Omnicell To Present At The 12th Annual Wells Fargo Securities Healthcare Conference finance.yahoo.com - August 31 at 8:13 AM
	Omnicell, Inc. (OMCL) Expected to Post Earnings of $0.41 Per Share www.americanbankingnews.com - August 29 at 6:18 PM
	Analyzing Omnicell (OMCL) and Allscripts Healthcare Solutions (MDRX) www.americanbankingnews.com - August 22 at 2:10 AM
	Dan S. Johnston Sells 16,400 Shares of Omnicell, Inc. (OMCL) Stock www.americanbankingnews.com - August 18 at 7:46 PM
	Head to Head Survey: Omnicell (OMCL) versus Fluidigm (FLDM) www.americanbankingnews.com - August 17 at 12:20 PM
	Omnicell Announces Enhancements to its Patient Management Access Portal (PMAP) for Improved Patient Adherence and Pharmacy Workflow finance.yahoo.com - August 17 at 6:31 AM
	Omnicell, Inc. (OMCL) EVP Robin Gene Seim Sells 15,109 Shares www.americanbankingnews.com - August 16 at 7:59 PM
	Omnicell, Inc. (NASDAQ:OMCL) Expected to Announce Quarterly Sales of $191.90 Million www.americanbankingnews.com - August 13 at 7:56 AM
	Zacks: Analysts Expect Omnicell, Inc. (OMCL) to Post $0.20 EPS www.americanbankingnews.com - August 11 at 4:46 PM
	Omnicell, Inc. (NASDAQ:OMCL) VP Peter J. Kuipers Sells 18,054 Shares www.americanbankingnews.com - August 9 at 10:20 PM
	Omnicell, Inc. (NASDAQ:OMCL) VP Sells $581,945.00 in Stock www.americanbankingnews.com - August 9 at 8:22 PM
	Omnicell, Inc. (OMCL) VP Sells $1,056,254.62 in Stock www.americanbankingnews.com - August 8 at 7:44 PM
	Omnicell, Inc. (NASDAQ:OMCL) Receives Consensus Rating of "Buy" from Analysts www.americanbankingnews.com - August 8 at 2:44 PM
	Veeva Systems (VEEV) & Omnicell (OMCL) Head to Head Survey www.americanbankingnews.com - August 5 at 8:30 AM
	Comparing Allscripts Healthcare Solutions (MDRX) & Omnicell (NASDAQ:OMCL) www.americanbankingnews.com - August 2 at 10:14 PM
	Insider Selling: Omnicell, Inc. (NASDAQ:OMCL) Chairman Sells 40,000 Shares of Stock www.americanbankingnews.com - August 1 at 7:28 PM
	Reviewing Castlight Health, inc. (CSLT) and Omnicell (NASDAQ:OMCL) www.americanbankingnews.com - July 31 at 12:34 AM
	Omnicell, Inc. (OMCL) Receives Hold Rating from Piper Jaffray Companies www.americanbankingnews.com - July 30 at 11:36 AM
	Omnicell Inc. (OMCL) Has Surged To A New High After Q2 Report www.nasdaq.com - July 29 at 6:02 AM
	Randall A. Lipps Sells 37,500 Shares of Omnicell, Inc. (NASDAQ:OMCL) Stock www.americanbankingnews.com - July 28 at 7:11 PM
	Omnicell, Inc. (OMCL) PT Raised to $49.00 www.americanbankingnews.com - July 28 at 12:25 PM
	Omnicell, Inc. (NASDAQ:OMCL) PT Raised to $52.00 www.americanbankingnews.com - July 28 at 9:12 AM
	Omnicell Achieves Record Revenue in the Second Quarter 2017 finance.yahoo.com - July 28 at 6:28 AM
	Edited Transcript of OMCL earnings conference call or presentation 27-Jul-17 8:30pm GMT finance.yahoo.com - July 28 at 6:28 AM
	Omnicell tops Street 2Q forecasts finance.yahoo.com - July 28 at 6:28 AM
	Omnicell, Inc. (OMCL) Updates FY17 Earnings Guidance www.americanbankingnews.com - July 28 at 12:21 AM
	Omnicell, Inc. (NASDAQ:OMCL) Releases Q3 Earnings Guidance www.americanbankingnews.com - July 28 at 12:21 AM
	Omnicell, Inc. (OMCL) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS www.americanbankingnews.com - July 27 at 9:21 PM
	Greater Hudson Valley Health System Adds New XT Series to Expand Omnicell Partnership finance.yahoo.com - July 27 at 6:05 AM
	Omnicell, Inc. (OMCL) Expected to Announce Quarterly Sales of $173.85 Million www.americanbankingnews.com - July 26 at 3:53 PM
	White River Health System Selects Omnicell's Medication Management Solutions for Patient Safety and Long-Term Success finance.yahoo.com - July 26 at 6:04 AM
	Omnicell, Inc. (OMCL) Rating Reiterated by Cantor Fitzgerald www.americanbankingnews.com - July 25 at 10:13 PM
	Critical Comparison: Simulations Plus (SLP) versus Omnicell (OMCL) www.americanbankingnews.com - July 24 at 8:22 PM
	Omnicell Launches XT Series Automated Dispensing Cabinets for Supply Management finance.yahoo.com - July 24 at 2:24 PM
	Omnicell to Release Second Quarter 2017 Earnings Results on July 27, 2017 finance.yahoo.com - July 22 at 7:18 AM
	Omnicell, Inc. (NASDAQ:OMCL) Given Average Rating of "Buy" by Brokerages www.americanbankingnews.com - July 14 at 3:18 PM
	ETFs with exposure to Omnicell, Inc. : July 10, 2017 finance.yahoo.com - July 11 at 6:21 AM
	Omnicell, Inc. (NASDAQ:OMCL) Rating Increased to Hold at Zacks Investment Research www.americanbankingnews.com - July 4 at 1:07 PM

Omnicell (OMCL) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by MarketBeat.com Staff

Omnicell Company Profile (NASDAQ:OMCL)

About Omnicell (NASDAQ:OMCL)

What is Omnicell's stock symbol?

How were Omnicell's earnings last quarter?

When will Omnicell make its next earnings announcement?

What guidance has Omnicell issued on next quarter's earnings?

Where is Omnicell's stock going? Where will Omnicell's stock price be in 2017?

What are analysts saying about Omnicell stock?

Who are some of Omnicell's key competitors?

Who are Omnicell's key executives?

Who owns Omnicell stock?

Who sold Omnicell stock? Who is selling Omnicell stock?

Who bought Omnicell stock? Who is buying Omnicell stock?

How do I buy Omnicell stock?

What is Omnicell's stock price today?

Analyst Ratings

Earnings

Estimates

Dividends

Insider Trades

Headlines

Social

Chart